Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Phase II study of erlotinib (Tarceva, OSI774) in...
Conference

Phase II study of erlotinib (Tarceva, OSI774) in women with recurrent or metastatic endometrial cancer - NCICIND 148.

Authors

Oza AM; Elit L; Eisenhauer E; Hoskins PJ; Biagi J; Carey M; Dubuc-Lissoir J; Dundas G; Stuart G; Matthews S

Volume

9

Pagination

pp. 6094S-6094S

Publisher

AMER ASSOC CANCER RESEARCH

Publication Date

December 1, 2003

Name of conference

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Conference place

BOSTON, MASSACHUSETTS

Conference start date

November 17, 2003

Conference end date

November 21, 2003

Conference proceedings

CLINICAL CANCER RESEARCH

Issue

16

ISSN

1078-0432